-
Injured Australian swim star O'Callaghan pulls out of PanPacs
-
Veteran Wallabies playmaker Quade Cooper eyes World Cup comeback
-
California lifeguards wiped out from extreme weather
-
FIFA scraps private investment plan after backlash
-
FIFA scraps private investment plan after backlash: Infantino
-
US plans steep water cuts for southwest amid Colorado River crisis
-
South Africa's WAFCON hopes hang in the balance after dramatic draw
-
Nakashima ousts top seed de Minaur, Osaka advances at Washington
-
Hunter Bell cruises to Commonwealth gold, Pathirage stuns javelin stars
-
Nakashima ousts top seed de Minaur and Osaka advances at Washington
-
Amazon surges as US stocks shrug off bond yield worries
-
Nakashima ousts defending champion de Minaur to reach Washington semis
-
Google rolls back new satellite image AI tool after backlash
-
Magaia salvages last-gasp WAFCON draw for South Africa
-
Ryu leads in bid for third straight major at women's British Open
-
Forever chemicals and pesticides under Trump: what to know
-
Fire-hit France region 'coming up for air' as main blaze calms
-
US announces steep water cuts for three states amid Colorado River crisis
-
Wembanyama to get signature shoe in Nike contract extension: reports
-
EU grapples with migrant crisis in Spain's N. Africa enclave
-
Oil giants report blowout profits on war, warn high gas prices could persist
-
Hungary to shut nuclear plant as heatwave hits central Europe
-
Google launches new satellite image AI tool, alarming researchers
-
Strengthening El Nino 'adding fuel to a planet already on fire': UN chief
-
Eddie Howe resigns as Newcastle boss to 'recharge'
-
Tech-fuelled rally fizzles as oil prices rise
-
High winds hamper firefighting efforts in western Turkey
-
Chelsea's Mudryk cleared to play after doping ban appeal
-
Howe resigns as Newcastle boss
-
A side of oysters for France's flat-out firefighters
-
Full-scale tour will benefit All Blacks, says coach Rennie
-
England cricket chief Key refuses to rule out Stokes return
-
US Fed dissenters call for rate hikes over sustained inflation
-
New blazes in Greece as strong winds hamper firefighting
-
Trump and far-right seize on Spanish migration crisis
-
Springboks star Feinberg-Mngomezulu back for Argentina Test
-
Hamas agrees to disarm under Trump plan
-
Shops closed, businesses quiet as Spain's Ceuta faces migrant surge
-
French, Italian winegrowers face earliest ever harvest
-
Chelsea fined £10mn, handed suspended transfer ban for breaching agent rules
-
Alarm over climate-linked low level of German waterways
-
Residents defend Spain’s ancient 'El Abuelo' tree from flames
-
UK court rejects challenge against new Chinese embassy in London
-
Forever chemicals and pesticides: what to know
-
New York sues online prediction markets giant Kalshi
-
Spaniard Santi Denia takes over as Czech Republic coach
-
Commerzbank agrees to talks with UniCredit after two-year standoff
-
EU races to contain new migrant crisis as thousands cross into Spain's N. Africa enclave
-
A rumour, a rush: chaos at Morocco border with Spain's Ceuta
-
Profits surge at US oil giant amid Iran war supply shock
Trump announces Pfizer deal he says will lower certain drug prices
The Trump administration on Tuesday announced a deal granting Pfizer a three-year reprieve on planned tariffs as the pharmaceutical giant vowed to voluntarily lower the prices of unspecified drugs for US purchase.
President Donald Trump, flanked by top health officials, was scant on details regarding what or how many drugs were included in the agreement, the announcement of which came as Washington faced a looming government shutdown.
Under the deal Pfizer is to charge "Most Favored Nation" pricing -- matching the lowest price offered in other wealthy nations -- to Medicaid, the US health insurance program for low-income Americans.
The White House also said it would unveil a website -- called TrumpRx -- that would allow consumers to directly purchase some medications from manufacturers at discounted rates.
Like Trump, Pfizer CEO Albert Bourla heralded the deal as a great achievement, although a statement from the company was equally vague on specifics.
The company did say a "large majority" of "primary care treatments and some select specialty brands" could be offered at savings from 50 percent to 85 percent.
"We now have the certainty and stability we need on two critical fronts, tariffs and pricing, that have suppressed the industry's valuations to historic lows," said Bourla.
Part of the deal included Pfizer agreeing to "invest $70 billion to reshore domestic manufacturing facilities" to the United States.
- Wider impact unclear -
Trump's initiative revives drug-pricing efforts from his first term. The president has taken steps since returning to the White House to pressure pharmaceutical companies into voluntarily lowering their prices.
In July the US leader sent letters to leading pharmaceutical companies demanding they lower drug prices.
Democrats have long indicated that they, too, would like to lower drug prices.
In a report released Monday, independent Senator Bernie Sanders said that Trump's efforts on the issue had "made headlines" but had done "little beyond that."
The member of the Senate's health committee said in his report that since Trump sent the letters over the summer, the prices of 87 drugs actually increased.
Drug costs for consumers in the United States can depend on several variables, notably insurance coverage.
Many people receive insurance through an employer, the health insurance market or government programs including Medicare, which is for seniors, and the safety net Medicaid.
It is not clear how Tuesday's deal will impact drug pricing in the commercial insurance market.
The announcement comes as drugmakers gird for a 100-percent tariff Trump said he would impose on branded pharmaceutical products entering the country from October 1 -- unless companies were building manufacturing plants in the United States.
But details surrounding the rollout remain unclear.
Since returning to the presidency in January, Trump has imposed sector-specific tariffs on imports like steel, aluminum and autos, while launching investigations into other areas like pharmaceuticals that could lead to new levies.
Asked Tuesday about the timeline for fresh tariffs, Commerce Secretary Howard Lutnick said the Trump administration plans to allow negotiations with companies to play out.
A.Ammann--VB